vadadustat vadadustat vadadustat is an experimental medication which acts as a hif prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. it is in phase iii clinical trials for the treatment of anemia caused by chronic kidney disease. vadadustatclinical dataother namesakb-6548, pg-1016548atc codeb03xa08 (who) identifiers iupac name 2-(amino)acetic acid cas number1000025-07-9pubchem cid23634441chemspider34958379uniii60w9520vvkeggd11078echa infocard100.248.991 chemical and physical dataformulac14h11cln2o4molar mass306.70 g·mol−13d model (jsmol)interactive image smiles oc1cc(cnc1c(=o)ncc(=o)o)c2cccc(cl)c2 inchi inchi=1s/c14h11cln2o4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18h,7h2,(h,17,21)(h,19,20)key:jgrxmpyutjltkt-uhfffaoysa-n society and culture legal status on 23 february 2023, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product vafseo, intended for the treatment of symptomatic anemia in adults with chronic kidney disease who are on chronic dialysis. the applicant for this medicinal product is akebia europe limited.